Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
89% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. MYGN: No Debt )
MYGN' s 10-Year Cash to Debt Range
Min: 16.5   Max: No Debt
Current: No Debt

Equity to Asset 0.88
MYGN's Equity to Asset is ranked higher than
94% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. MYGN: 0.88 )
MYGN' s 10-Year Equity to Asset Range
Min: 0.71   Max: 0.96
Current: 0.88

0.71
0.96
Interest Coverage No Debt
MYGN's Interest Coverage is ranked higher than
92% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. MYGN: No Debt )
MYGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 18.71
M-Score: -2.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 29.21
MYGN's Operating margin (%) is ranked higher than
98% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. MYGN: 29.21 )
MYGN' s 10-Year Operating margin (%) Range
Min: -134.85   Max: 39.24
Current: 29.21

-134.85
39.24
Net-margin (%) 18.37
MYGN's Net-margin (%) is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. MYGN: 18.37 )
MYGN' s 10-Year Net-margin (%) Range
Min: -89.39   Max: 42
Current: 18.37

-89.39
42
ROE (%) 19.43
MYGN's ROE (%) is ranked higher than
95% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. MYGN: 19.43 )
MYGN' s 10-Year ROE (%) Range
Min: -25.88   Max: 30.71
Current: 19.43

-25.88
30.71
ROA (%) 17.15
MYGN's ROA (%) is ranked higher than
98% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. MYGN: 17.15 )
MYGN' s 10-Year ROA (%) Range
Min: -23.02   Max: 28.73
Current: 17.15

-23.02
28.73
ROC (Joel Greenblatt) (%) 243.74
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. MYGN: 243.74 )
MYGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238.09   Max: 362.64
Current: 243.74

-238.09
362.64
Revenue Growth (3Y)(%) 31.50
MYGN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. MYGN: 31.50 )
MYGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.7   Max: 44.9
Current: 31.5

1.7
44.9
EBITDA Growth (3Y)(%) 27.00
MYGN's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. MYGN: 27.00 )
MYGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.6   Max: 47.2
Current: 27

-10.6
47.2
EPS Growth (3Y)(%) 26.90
MYGN's EPS Growth (3Y)(%) is ranked higher than
94% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. MYGN: 26.90 )
MYGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -16.6   Max: 66.6
Current: 26.9

-16.6
66.6
» MYGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MYGN Guru Trades in Q4 2013

Chase Coleman 1,202,100 sh (New)
Third Avenue Management 328,314 sh (New)
Louis Moore Bacon 165,000 sh (New)
Richard Snow 1,538,685 sh (+10989.6%)
Paul Tudor Jones 133,442 sh (+223.1%)
First Pacific Advisors 251,100 sh (+83.96%)
Joel Greenblatt 1,316,314 sh (+36.27%)
Ronald Muhlenkamp Sold Out
Manning & Napier Advisors, Inc Sold Out
Chuck Royce 10,843,075 sh (-1.49%)
Steven Cohen 40,914 sh (-83.44%)
Jim Simons 362,700 sh (-85.69%)
» More
Q1 2014

MYGN Guru Trades in Q1 2014

John Griffin 1,000,000 sh (New)
Jean-Marie Eveillard 284,826 sh (New)
Chase Coleman 2,345,921 sh (+95.15%)
Steven Cohen 70,402 sh (+72.07%)
Richard Snow 1,817,401 sh (+18.11%)
First Pacific Advisors 251,100 sh (unchged)
Third Avenue Management Sold Out
Joel Greenblatt 1,206,099 sh (-8.37%)
Chuck Royce 9,435,713 sh (-12.98%)
Louis Moore Bacon 87,902 sh (-46.73%)
Jim Simons 62,800 sh (-82.69%)
Paul Tudor Jones 6,905 sh (-94.83%)
» More
Q2 2014

MYGN Guru Trades in Q2 2014

Andreas Halvorsen 1,330,294 sh (New)
John Burbank 16,676 sh (New)
Paul Tudor Jones 12,833 sh (+85.85%)
First Pacific Advisors 251,100 sh (unchged)
Jean-Marie Eveillard Sold Out
Louis Moore Bacon Sold Out
John Griffin Sold Out
Chuck Royce 9,299,478 sh (-1.44%)
Joel Greenblatt 1,117,351 sh (-7.36%)
Chase Coleman 1,900,000 sh (-19.01%)
Jim Simons 49,200 sh (-21.66%)
Richard Snow 1,091,227 sh (-39.96%)
» More
Q3 2014

MYGN Guru Trades in Q3 2014

Jim Simons 60,474 sh (+22.91%)
First Pacific Advisors 251,100 sh (unchged)
Chase Coleman 1,900,000 sh (unchged)
John Burbank Sold Out
Andreas Halvorsen Sold Out
Richard Snow 1,055,014 sh (-3.32%)
Chuck Royce 8,906,065 sh (-4.23%)
Joel Greenblatt 869,531 sh (-22.18%)
Paul Tudor Jones 7,976 sh (-37.85%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-09-30 Sold Out 0.23%$35.44 - $40.41 $ 36.12-3%0
Joel Greenblatt 2014-09-30 Reduce -22.18%0.12%$35.44 - $40.41 $ 36.12-3%869531
John Burbank 2014-09-30 Sold Out 0.01%$35.44 - $40.41 $ 36.12-3%0
Richard Snow 2014-06-30 Reduce -39.96%0.96%$33.1 - $42.21 $ 36.12-3%1091227
John Griffin 2014-06-30 Sold Out 0.38%$33.1 - $42.21 $ 36.12-3%0
Andreas Halvorsen 2014-06-30 New Buy0.23%$33.1 - $42.21 $ 36.12-3%1330294
Jean-Marie Eveillard 2014-06-30 Sold Out 0.03%$33.1 - $42.21 $ 36.12-3%0
John Burbank 2014-06-30 New Buy0.01%$33.1 - $42.21 $ 36.12-3%16676
John Griffin 2014-03-31 New Buy0.38%$20.79 - $38.17 $ 36.1218%1000000
Richard Snow 2014-03-31 Add 18.11%0.37%$20.79 - $38.17 $ 36.1218%1817401
Third Avenue Management 2014-03-31 Sold Out 0.13%$20.79 - $38.17 $ 36.1218%0
Jean-Marie Eveillard 2014-03-31 New Buy0.03%$20.79 - $38.17 $ 36.1218%284826
Ronald Muhlenkamp 2013-12-31 Sold Out 2.3%$20.79 - $30.65 $ 36.1242%0
Richard Snow 2013-12-31 Add 10989.6%1.29%$20.79 - $30.65 $ 36.1242%1538685
Joel Greenblatt 2013-12-31 Add 36.27%0.18%$20.79 - $30.65 $ 36.1242%1316314
Third Avenue Management 2013-12-31 New Buy0.13%$20.79 - $30.65 $ 36.1242%328314
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics - Oct 08, 2014

Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. It was the Fund’s largest holding at the end of June.

From Chuck Royce (Trades, Portfolio)’s Royce Premier Fund Second Quarter 2014 Manager Commentary.

Check out Chuck Royce latest stock trades

Baron Funds Comments on Myriad Genetics Inc. - Jun 06, 2013

Myriad Genetics, Inc. (MYGN)develops, markets and performs novel genetic tests in its own proprietary labs. It has a lab in Utah and recently opened a second facility in Munich, Germany to process international tests (a big opportunity as nearly all of current revenues are from U.S. customers). MYGN performed about 150,000 tests in 2012 for breast, colon and skin cancers. The company has 193 issued patents, as well as numerous patent applications in the U.S. and foreign countries. It also has numerous trade secrets (including a one-of-a-kind breast cancer genetic mutation database), which are likely even more important than the patents. We believe that MYGN has the ability to grow revenues by expanding its current test menu as well as growing its European operations and introducing new tests (prostate cancer and companion diagnostics for pharmaceutical usage). (Randy Gwirtzman)

From Baron Funds’ first quarter 2013 commentary.


Check out Ron Baron latest stock trades

Top Ranked Articles about Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics
Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.50
MYGN's P/E(ttm) is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 20.50 )
MYGN' s 10-Year P/E(ttm) Range
Min: 9.09   Max: 80.49
Current: 20.5

9.09
80.49
P/B 3.70
MYGN's P/B is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. MYGN: 3.70 )
MYGN' s 10-Year P/B Range
Min: 1.89   Max: 8.23
Current: 3.7

1.89
8.23
P/S 3.80
MYGN's P/S is ranked higher than
72% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. MYGN: 3.80 )
MYGN' s 10-Year P/S Range
Min: 2.32   Max: 14.79
Current: 3.8

2.32
14.79
PFCF 32.60
MYGN's PFCF is ranked higher than
85% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 32.60 )
MYGN' s 10-Year PFCF Range
Min: 7.63   Max: 140.77
Current: 32.6

7.63
140.77
EV-to-EBIT 11.54
MYGN's EV-to-EBIT is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 11.54 )
MYGN' s 10-Year EV-to-EBIT Range
Min: -102.6   Max: 52.4
Current: 11.54

-102.6
52.4
PEG 0.77
MYGN's PEG is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 0.77 )
MYGN' s 10-Year PEG Range
Min: 0.43   Max: 0.94
Current: 0.77

0.43
0.94
Shiller P/E 23.70
MYGN's Shiller P/E is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 23.70 )
MYGN' s 10-Year Shiller P/E Range
Min: 14.52   Max: 502.6
Current: 23.7

14.52
502.6
Current Ratio 4.95
MYGN's Current Ratio is ranked higher than
88% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. MYGN: 4.95 )
MYGN' s 10-Year Current Ratio Range
Min: 2.2   Max: 20.28
Current: 4.95

2.2
20.28
Quick Ratio 4.59
MYGN's Quick Ratio is ranked higher than
87% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. MYGN: 4.59 )
MYGN' s 10-Year Quick Ratio Range
Min: 2.2   Max: 20.28
Current: 4.59

2.2
20.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.00
MYGN's Price/Net Cash is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 42.00 )
MYGN' s 10-Year Price/Net Cash Range
Min: 2.9   Max: 70.43
Current: 42

2.9
70.43
Price/Net Current Asset Value 20.00
MYGN's Price/Net Current Asset Value is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 20.00 )
MYGN' s 10-Year Price/Net Current Asset Value Range
Min: 2.72   Max: 56.34
Current: 20

2.72
56.34
Price/Tangible Book 7.70
MYGN's Price/Tangible Book is ranked higher than
72% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. MYGN: 7.70 )
MYGN' s 10-Year Price/Tangible Book Range
Min: 1.53   Max: 18.98
Current: 7.7

1.53
18.98
Price/DCF (Projected) 1.10
MYGN's Price/DCF (Projected) is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 1.10 )
MYGN' s 10-Year Price/DCF (Projected) Range
Min: 0.64   Max: 22.85
Current: 1.1

0.64
22.85
Price/Median PS Value 0.60
MYGN's Price/Median PS Value is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. MYGN: 0.60 )
MYGN' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 6.93
Current: 0.6

0.35
6.93
Price/Peter Lynch Fair Value 0.80
MYGN's Price/Peter Lynch Fair Value is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 0.80 )
MYGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 1.7
Current: 0.8

0.43
1.7
Price/Graham Number 2.60
MYGN's Price/Graham Number is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 2.60 )
MYGN' s 10-Year Price/Graham Number Range
Min: 0.97   Max: 3.08
Current: 2.6

0.97
3.08
Earnings Yield (Greenblatt) 8.80
MYGN's Earnings Yield (Greenblatt) is ranked higher than
95% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. MYGN: 8.80 )
MYGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 22.7
Current: 8.8

1.9
22.7
Forward Rate of Return (Yacktman) 29.52
MYGN's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. MYGN: 29.52 )
MYGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.9   Max: 33.1
Current: 29.52

-19.9
33.1

Analyst Estimate

Jun15 Jun16
Revenue(Mil) 797 852
EPS($) 1.81 2.31
EPS without NRI($) 1.81 2.31

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Companys business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 


More From Other Websites
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience Dec 22 2014
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience Dec 22 2014
12:12 pm Myriad Genetics receives FDA approval of BRACAnalysis CDx as companion diagnostic for... Dec 21 2014
Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM)... Dec 19 2014
Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM)... Dec 19 2014
Myriad, Omaha Steaks, Abbott Healthcare: Intellectual Property Dec 18 2014
Myriad Loses Appeals Court Bid to Block Breast Cancer Tests Dec 17 2014
Myriad Genetics Unveils Positive Cancer Study Results Dec 10 2014
Three New Myriad Studies Highlighted at 2014 San Antonio Breast Cancer Symposium Dec 09 2014
Three New Myriad Studies Highlighted at 2014 San Antonio Breast Cancer Symposium Dec 09 2014
MYRIAD GENETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 05 2014
Myriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium Dec 03 2014
Myriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium Dec 03 2014
Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years Dec 02 2014
Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years Dec 02 2014
Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test Nov 21 2014
Myriad's Vectra DA: A Better Indicator for Rheumatoid Arthritis Nov 20 2014
TESARO and Myriad Announce Companion Diagnostics Collaboration Nov 20 2014
TESARO and Myriad Announce Companion Diagnostics Collaboration Nov 20 2014
Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK